CRSP: $2.4B Enterprise Value With An Approved Drug And A Loaded Pipeline - The Disconnect Has A Name

CRISPR Therapeutics (CRSP) beat Q2 2026 EPS estimates and posted $76 million in CASGEVY revenue, then the stock rallied less than 3% in regular trading and ticked up modestly after hours. The muted reaction tells you where the market's attention is: on quarterly burn, on the path to profitability, on the fact that this is still a company losing money. That's a understandable focus - but it's also the wrong variable. The real question for CRSP is whether the in vivo pipeline can justify a second growth curve while the balance sheet has more than enough runway to get there.

The market is pricing CRSP like a pre-commercial gene editor with hope attached. The math says otherwise.

1. $76 million in quarterly CASGEVY revenue - not a rounding error, not a one-off. CASGEVY, the ex vivo gene-edited therapy for sickle cell disease and beta-thalassemia developed with Vertex Pharmaceuticals, generated $76 million in Q2 2026. That's the fourth quarter of actual commercial revenue, and the trajectory matters more than the absolute number. CASGEVY exceeded $100 million in total 2025 revenue with more than 60 patient infusions - a three-fold increase in patient initiations over 2024. The FDA just approved a label expansion to patients as young as two years old, dramatically widening the addressable population. This isn't a pipeline option anymore. It's a cash-flow-generating asset with multi-country approvals across the U.S., EU, UK, Canada, and multiple Middle Eastern markets.

2. $2.36 billion in cash. $2.4 billion enterprise value. The balance sheet is the anchor. Cash, cash equivalents, and marketable securities hit $2.364 billion as of June 30, 2026, up from roughly $2 billion at year-end 2025 after a convertible note offering in March. With total market cap at $4.78 billion, CRSP's enterprise value - market cap minus cash - sits around $2.4 billion. You're paying $2.4 billion for a company with an approved drug showing early commercial traction, a current ratio of 17.96 (meaning it has $18 in current assets for every $1 of current liabilities), and $911 million in total debt against $1.8 billion in equity. At an estimated quarterly burn rate of roughly $80-$90 million (R&D of ~$69 million plus G&A of ~$17 million in Q1, before revenue offset), the cash runway extends into 2029 or beyond. The capital risk is minimal.

3. The H2 pipeline is the disconnect. This is where the market's valuation model falls apart. CRSP isn't just CASGEVY. The in vivo liver-editing portfolio - using lipid nanoparticles to deliver CRISPR directly into the body rather than requiring the complex ex vivo cell manufacturing process - represents an entirely different business model with common-disease addressable markets. CTX310, targeting ANGPTL3 to lower triglycerides and LDL cholesterol, already showed dose-dependent reductions of up to 82% in triglycerides and 86% in LDL in Phase 1, with no dose-limiting toxicities. That data was published in the New England Journal of Medicine. An update is expected in H2 2026. CTX611, an siRNA therapy targeting Factor XI for thromboembolic conditions (developed with Sirius Therapeutics), has Phase 2 data coming in H2. Zugo-cel, an allogeneic CAR-T therapy for oncology and autoimmune diseases, is also expected to deliver updates. The Lp(a) program (CTX320/321), hypertension program (CTX340), and alpha-1 antitrypsin deficiency program (CTX460) round out the cardiology and rare disease pipeline. Five to seven data points from a wholly-owned in vivo portfolio in the second half of a single year. The market is assigning $2.4 billion enterprise value to that entire book.

   

4. Peer comparison shows the gap. Among pure-play gene-editing companies, CRSP sits at $4.78 billion market cap versus Intellia Therapeutics at $1.51 billion and Beam Therapeutics at $2.67 billion. Both peers lack an approved commercial product - CRSP is the only one in the group with CASGEVY generating actual revenue. Editas Medicine, at $407 million, has been hollowed out by a series of setbacks. On the other end, Vertex Pharmaceuticals trades at a $119.5 billion market cap and 27.5x trailing earnings, but CRSP's $2.4 billion net enterprise value means you're buying the optionality on multiple in vivo programs at a fraction of what Vertex's gene-editing business would cost if spun out. AInvest's aggregate signal labels CRSP a Buy, which aligns with the structural setup even if the consensus hasn't pushed the price to reflect it.

The counterargument. The burn is real - TTM free cash flow was negative $426 million - and in vivo gene editing remains an unproven modality at commercial scale. CTX310's Phase 1 results are impressive but Phase 1b and later-stage trials often reveal durability and manufacturing challenges that don't appear in small cohorts. If CRSP fails to demonstrate that its lipid nanoparticle platform can replicate CTX310's early signal in larger patient groups, the pipeline valuation collapses. That's the risk. But the cash position means the company can absorb setbacks and keep the portfolio moving without dilution pressure.

The one number. At roughly $2.4 billion enterprise value with $76 million in quarterly revenue from an approved drug, you're paying about 32x annualized CASGEVY revenue for a company that also owns CTX310, CTX611, zugo-cel, and the broader in vivo portfolio outright. If CASGEVY continues to accelerate toward the multi-billion-dollar ceiling management has hinted at, and even one in vivo program demonstrates durable Phase 2 signal in H2, the math rewrites itself. The stock, down 37% from its 52-week high, is reflecting the bear case for a business that may have just started executing the bull case.